Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia

• Published in: Blood Vol. 128; no. 5; pp. 686 - 698
• Main Authors: Metzeler, Klaus H., Herold, Tobias, Rothenberg-Thurley, Maja, Amler, Susanne, Sauerland, Maria C., Görlich, Dennis, Schneider, Stephanie, Konstandin, Nikola P., Dufour, Annika, Bräundl, Kathrin, Ksienzyk, Bianka, Zellmeier, Evelyn, Hartmann, Luise, Greif, Philipp A., Fiegl, Michael, Subklewe, Marion, Bohlander, Stefan K., Krug, Utz, Faldum, Andreas, Berdel, Wolfgang E., Wörmann, Bernhard, Büchner, Thomas, Hiddemann, Wolfgang, Braess, Jan, Spiekermann, Karsten
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 04-08-2016
• Subjects: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cytogenetic Analysis; DNA Mutational Analysis; Female; Gene Frequency - genetics; Genetic Predisposition to Disease; Humans; Leukemia, Myeloid, Acute - genetics; Male; Middle Aged; Multivariate Analysis; Mutation - genetics; Prognosis; Risk Factors; Survival Analysis; Young Adult
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood-2016-01-693879

The clinical and prognostic relevance of many recently identified driver gene mutations in adult acute myeloid leukemia (AML) is poorly defined. We sequenced the coding regions or hotspot areas of 68 recurrently mutated genes in a cohort of 664 patients aged 18 to 86 years treated on 2 phase 3 trials of the German AML Cooperative Group (AMLCG). The median number of 4 mutations per patient varied according to cytogenetic subgroup, age, and history of previous hematologic disorder or antineoplastic therapy. We found patterns of significantly comutated driver genes suggesting functional synergism. Conversely, we identified 8 virtually nonoverlapping patient subgroups, jointly comprising 78% of AML patients, that are defined by mutually exclusive genetic alterations. These subgroups, likely representing distinct underlying pathways of leukemogenesis, show widely divergent outcomes. Furthermore, we provide detailed information on associations between gene mutations, clinical patient characteristics, and therapeutic outcomes in this large cohort of uniformly treated AML patients. In multivariate analyses including a comprehensive set of molecular and clinical variables, we identified DNMT3A and RUNX1 mutations as important predictors of shorter overall survival (OS) in AML patients <60 years, and particularly in those with intermediate-risk cytogenetics. NPM1 mutations in the absence of FLT3-ITD, mutated TP53, and biallelic CEBPA mutations were identified as important molecular prognosticators of OS irrespective of patient age. In summary, our study provides a comprehensive overview of the spectrum, clinical associations, and prognostic relevance of recurrent driver gene mutations in a large cohort representing a broad spectrum and age range of intensively treated AML patients.
•We present comprehensive information on genetic driver events in a uniformly treated cohort of 664 adult AML patients aged 18 to 86 years.•Mutations in NPM1, FLT3, CEBPA, TP53, and, in patients <60 years, DNMT3A and RUNX1, are the most important molecular risk factors in AML.